Barcelona

• A Phase 2 study of INBRX-109 in adults with a type of unresectable or metastasized cancer of the bones and joints (Conventional Chondrosarco … Ended recruitment
  2024-517528-20-00 4 2022-04-19 Unresectable or metastatic conventional chondrosarcoma
• A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Non Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE) Ended recruitment
  2024-512745-16-00 5 2022-04-13 Non–Transfusion-Dependent Alpha- or Beta-Thalassemia
• A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular A … Ended recruitment
  2023-506761-65-00 10 2022-04-08 Spinal Muscular Atrophy (SMA)
• Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Ca … Ended recruitment
  2023-506265-65-00 1 2022-04-07 Localized Bladder Cancer
• A Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non−Small-Cell Lung Ca … Ended recruitment
  2024-513225-23-00 4 2022-04-07 Non-small cell lung cancer
• Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended recruitment
  2023-503517-30-00 5 2022-04-01 Extensive-stage small-cell lung cancer
• Phase 3 study of pembrolizumab vs chemotherapy in dMMR advanced or recurrent endometrial carcinoma Ended recruitment
  2023-506361-56-00 5 2022-04-01 Endometrial cancer
• Master Protocol of Sotorasib (AMG 510) in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 101) Ended recruitment
  2023-506794-35-00 3 2022-04-01 Advanced Solid Tumors Kirsten Rat Sarcoma (KRAS) pG12C Mutation
• A study to assess the Safety, Tolerability, Pharmacokinetics and Anti tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lun … Ended recruitment
  2024-512127-36-00 9 2022-03-31 Non-Small Cell Lung Cancer
• Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis Ended recruitment
  2023-504597-37-00 5 2022-03-25 Focal segmental glomerulosclerosis
• Tuvusertib (M1774) in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301) Ended recruitment
  2024-515848-23-00 1 2022-03-18 Metastatic or Locally Advanced Unresectable Solid Tumors
• Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 Ended recruitment
  2024-516293-29-01 4 2022-03-17 Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic
• Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer Ended recruitment
  2023-506771-10-00 5 2022-03-11 Breast Neoplasm, Neoplasm Metastasis
• Master Protocol for Avelumab Continuation Study. Ended recruitment
  2023-509466-38-00 5 2022-03-08 Cancer
• A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended recruitment
  2023-503640-14-00 5 2022-02-17 Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
• Assessment of effectiveness and safety of luspatercept in patients suffering from lower-risk myelodysplastic syndrome. Ended recruitment
  2024-515069-33-00 5 2022-02-15 Patients with anemia due to IPSS-R defined very low-, low-, or interme
• A study of lurbinectedin in combination with atezolizumab compared with atezolizumab as maintenance therapy in participants with extensive-s … Ended recruitment
  2023-503868-16-00 5 2022-02-14 Small-Cell Lung Cancer (SCLC)
• A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with I … Ended recruitment
  2024-515617-18-00 1 2022-02-14 Advanced clear cell renal cell carcinoma (ccRCC), non-clear cell renal
• A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can … Ended recruitment
  2023-503826-37-00 5 2022-02-11 Unresectable locally-advanced or metastatic HER2+ breast cancer
• A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Mu … Ended recruitment
  2023-506516-40-00 5 2022-02-11 Relapsing-Remitting Multiple Sclerosis
• A study to learn how well finerenone works; how safe it is; how it moves into, through, and out of the body; and the effects it has on the b … Ended recruitment
  2023-504884-17-00 5 2022-02-04 Proteinuria
• Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa … Ended recruitment
  2024-518304-53-00 5 2022-02-02 Relapsed or Refractory Multiple Myeloma (RRMM)
• Study BT5528-100 in Patients with Advanced Solid Tumors Associated with EphA2 Expression Ended recruitment
  2024-510655-36-00 7 2022-02-01 Advanced Malignancies Associated with EphA2 Expression
• Efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia Ended recruitment
  2023-509441-13-00 4 2022-01-31 Warm autoimmune hemolytic anemia

Showing 2,137–2,160 of 3,391 trials